FON-2022-0484 infographic - Phase III MANIFEST-2: pelabresib + ruxolitinib vs placebo + ruxolitinib in JAK inhibitor treatment-naive myelofibrosis
figure
posted on 2022-09-16, 13:15 authored by Claire N Harrison, Vikas K Gupta, Aaron T Gerds, Raajit Rampal, Srdan Verstovsek, Moshe Talpaz, Jean-Jacques Kiladjian, Ruben Mesa, Andrew T Kuykendall, Alessandro M Vannucchi, Francesca Palandri, Sebastian Grosicki, Timothy Devos, Eric Jourdan, Marielle J Wondergem, Haifa Kathrin Al-Ali, Veronika Buxhofer-Ausch, Alberto Alvarez-Larran, Andrea Patriarca, Marina Kremyanskaya, Adam J Mead, Sanjay Akhani, Yuri Sheikine, Gozde Colak, John Mascarenhas<p>Phase III MANIFEST-2: pelabresib +</p>
<p>ruxolitinib vs placebo + ruxolitinib in JAK</p>
<p>inhibitor treatment-naive myelofibrosis infographic</p>
